Follow The Filings

ROIV Roivant Sciences Ltd.

Health Care, filed as ROIVANT SCIENCES LTD (SHS), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q3, sold by 3

  • 5 Owners
  • Max 3.4%
  • $1.2B
  • 2 add 2 reduce 1 exit

In 2026 Q3, 2 managers added, 2 trimmed, and 1 sold out.

Who owns this now

Largest portfolio weights among holders, up to 3.4% (Farallon Capital Management). Not free-float ownership.

  1. Farallon Capital Management Add 3.4%
  2. David Einhorn Reduce 1.2%
  3. Andreas Halvorsen Add 0.76%
  4. Lee Ainslie Reduce 0.66%
  5. Ron Baron 0.01%

Who owns ROIV

Sorted by value, long equity only, as of 2026 Q3.

History
Farallon Capital Management 3.4%, was 2.3% Add +52.0% 21,745,533 $795M History
Andreas Halvorsen, Viking Global Investors 0.76%, was 0.64% Add +7.7% 6,757,326 $247M History
Lee Ainslie, Maverick Capital 0.66%, was 0.89% Reduce −18.4% 2,307,799 $84M History
David Einhorn, DME Capital Management 1.2%, was 1.9% Reduce −47.4% 1,131,747 $41M History
Ron Baron, BAMCO Inc. (Baron Capital) 0.01% Hold 125,000 $4.6M History
Polen Capital Management exited 2026 Q3 Last 2026 Q2 <0.01% Exit 0.00% 8,659 $306K History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ROIV's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ROIV insider trades
  • None no insider bought on the open market
  • $779M sold by 10 insiders outside a trading plan
  • $174M sold by 4 insiders under 10b5-1 plans
  1. Keith S. Manchester Director
    Sale
    $53.5M 1,381,762 shares at $38.75 19% of stake
    Traded Nov 16–17 Filed Nov 18
  2. Richard Pulik CFO
    Sale
    $12.5M 300,000 shares at $41.58 58% of stake
    Traded Nov 10–11 Filed Nov 12
  3. Eric Venker CEO
    Planned sale
    $7.6M 187,943 shares at $40.53 19% of stake
    Traded Nov 10 Filed Nov 12
  4. Eric Venker CEO
    Planned sale
    $7.3M 200,000 shares at $36.31 17% of stake
    Traded Nov 3 Filed Nov 5
  5. Eric Venker CEO
    Planned sale
    $7.3M 200,000 shares at $36.59 14% of stake
    Traded Oct 28 Filed Oct 30
  6. Eric Venker CEO
    Planned sale
    $7M 200,000 shares at $35.11 13% of stake
    Traded Oct 20 Filed Oct 22
  7. Melissa B. Epperly Director
    Planned sale
    $641K 17,750 shares at $36.10 54% of stake
    Traded Oct 1 Filed Oct 5
  8. Eric Venker CEO
    Planned sale
    $7.3M 200,000 shares at $36.62 11% of stake
    Traded Sep 30 Filed Oct 2
  9. Melissa B. Epperly Director
    Planned sale
    $196K 4,938 shares at $39.74 33% of stake
    Traded Sep 15 Filed Sep 17
  10. Meghan Fitzgerald Director
    Planned sale
    $203K 5,112 shares at $39.74 12% of stake
    Traded Sep 15 Filed Sep 17
  11. Meghan Fitzgerald Director
    Planned sale
    $798K 20,000 shares at $39.90 32% of stake
    Traded Sep 8 Filed Sep 10
  12. Eric Venker CEO
    Planned sale
    $7.2M 200,000 shares at $35.77 11% of stake
    Traded Aug 28 Filed Sep 1
  13. Mayukh Sukhatme President & CIO
    Sale
    $12.4M 335,174 shares at $36.88 1.8% of stake
    Traded Aug 19–21 Filed Aug 21

Also filed in the last 12 months, not counted as buying or selling: 44 option exercises, 41 share withholdings for taxes, 38 other transactions, 21 stock grants, 2 sales to cover taxes, and 1 gift.

Congress

1 member of Congress traded ROIV in the last three years: 2 buys and 2 sales.

All Congress trades
  1. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Oct 31, 2025 filed Nov 21, 2025
  2. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Oct 30, 2025 filed Nov 21, 2025
  3. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Oct 30, 2025 filed Nov 21, 2025
  4. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Jun 17, 2025 filed Aug 13, 2025

SEC filings

Recent issuer filings from EDGAR, 7 shown.

Filed Form Detail Links
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 7.01,9.01
SCHEDULE 13D/A —
8-K 5.07,9.01

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $61.28M $32.71M $29.05M
Net income -$1.01B $4.35B -$0.172B
Net margin * -1646.6% 13294.2% -592.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.8B $6.73B $5B
Total non-current assets * $591.02M $490.65M $436.88M
Total assets $2.39B $7.22B $5.44B
Total current liabilities $272.45M $266.76M $149.41M
Total non-current liabilities * $509.57M $507.2M $100.33M
Total equity $1.16B $5.97B $4.69B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$843.39M -$765.27M -$839.45M
Cash from investing -$0.044B $5.2B -$1.77B
Cash from financing $0.499B $0.419B -$1.22B
Net change in cash -$0.382B $4.86B -$3.82B

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf